Abstract: A pharmaceutical composition of a free amine benzophenanthridine alkaloid and a pharmaceutically acceptable carrier is disclosed. The composition is an antibacterial and antifungal agent.

Abstract: Pharmaceutical preparations for the treatment of hyperproliferative epidermal conditions comprising the specific negative growth factor activin A, and their use in methods of treatment of hyperproliferative epidermal conditions.

Abstract: Methods are provided for preparing compositions suitable for protecting irritated or damaged skin from further oxidative and biochemical damage and thus permitting natural healing processes to progress, for accelerating the rate of healing of burns and surgical wounds, and for increasing the size of hair follicles and the rate of hair growth. The compositions generally comprise precipitates formed by the complexation of peptone digests of various proteins with copper(II) salts, indium (III) salts, tin(II) salts and tin(IV) salts.

Abstract: The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or inhibited through the use of serine protease inhibitors, their analogs, salts, conjugates or derivatives.

Abstract: The topical drug delivery composition and method of the present invention provides a composition and method for delivering amounts of diclofenac effective for treating inflamed and/or painful joints or muscles percutaneously via a gel. Diclofenac sodium is solubilized in a mixture of water, a low molecular weight alcohol, and a glycol. In the present invention, the transdermal flux of diclofenac is unexpectedly enhanced by the addition of an ether alcohol and a fatty alcohol ester. The transdermal flux can be further enhanced by the addition of a glycol such as hexylene glycol.

Abstract: A skin care composition contains an antioxidant effective amount of a phenolic diterpene compound of the ferruginol type. The compounds can be dissolved, dispersed or encapsulated in cosmetic solutions, lotions, creams and liposomes to provide skin care products which reduce the accumulation of lipid peroxides and other biological oxidation products in the skin. Such compositions are effective agents against the production of peroxides in the skin resulting from sunlight, heat, radiation and the aging process.

Abstract: A therapeutic preparation for topical application to the skin for treating skin disorders such as minor burns, abrasions and the like, which contains myrrh oil.

Abstract: The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.

Abstract: A pharmaceutical composition for use in the transdermal administration of a medicament to both humans and animals, which composition comprises at least ingredients (1) and (2) of the following ingredients (1), (2) and (3), namely: (1) an effective amount of a medicament adapted for transdermal administration; (2) a transdermally transporting effective amount of a carrier for the medicament, which carrier is selected from semisolids and liquids at ambient temperatures, and which carrier comprises at least one compound selected from esters of C.sub.8-24 fatty acids, pharmaceutically acceptable aliphatic polyhydroxy compounds and non-volatile paraffins; (3) an optional medicament selected from antiinflammatory agents and antihistamines, effective to mitigate any skin-incompatibility characteristic which may otherwise be present. Administration is preferably by means of a matrix which comprises a porous, absorbent, perforate and flexible laminar solid support, having the composition absorbed thereon.

Abstract: Patients suffering from acne and/or pseudofolliculitis barbae are treated by applying to the skin of the patient an inhibitor of ornithine decarboxylase.

Abstract: This invention relates to methods for delipidation of skin or hair through the use of cyclodextrins and cyclodextrin derivatives such as hydroxypropyl .beta.-cyclodextrin. The invention also relates to cerumen removal methods involving introduction of cyclodextrins to the ear canal, followed by complexation of the cyclodextrin with cerumen components, and removal of the resulting cyclodextrin complexes. The cyclodextrin components are used in a substantially oil-free powdered or aqueous formulation without detergents, soaps, solvents, oils or other lipid-like agents.

Abstract: An anhydrous, topically-effective composition that resists phase separation and exhibits improved properties comprising a topically-active compound, such as an astringent salt; an improved suspending agent comprising a finely-divided silica and a suspending wax composition; and a suitable volatile liquid carrier, such as a volatile silicone or a volatile hydrocarbon. The suspending wax composition comprises a wax, an ester including at least 10 to about 32 carbon atoms and a volatile liquid carrier. The anhydrous, topically-effective composition is useful in topical cosmetic and medicinal preparations, such as antiperspirants, sunscreens and topical drug products, and is especially useful in cosmetic and medicinal preparations wherein an insoluble topically-active compound is dispersed throughout a liquid phase.

Abstract: Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to compositions comprising a mixture of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.

Abstract: The invention provides compounds of the general formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Abstract: Compositions containing 1.alpha.-hydroxyvitamin D homolog compounds in a suitable carrier and methods employing such compositions are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, dermal hydration and sebum secretion. Various formulations of the compositions including creams, lotions and ointments are disclosed for use topically, orally or parenterally in accordance with this invention.

Abstract: The present invention relates to new therapeutic uses of lipophilic extracts of Commiphora mukul, prepared from exudate of said plant, as well as the preparation of pure compounds or highly standardized fractions thereof as active ingredients. The extracts, the fractions thereof or the single pure active ingredients isolated therefrom proved to be useful in the treatment of inflammations, both of allergic origin and not, concerning skin and external mucosae, and in the symptomatic treatment of benign prostatic hypertrophy and in the resolutive treatment of acne.

Abstract: Products for cutaneous application with cosmetic and/or therapeutic effects, containing one or more active substances. This or these substances are carried by the microspheres of a polymer, dispersed in a liquid in which this polymer is not soluble.

Abstract: A medicine for skin diseases contains a fermented and condensed extract from the stems of Stevia Rebaudiana Bertoni as an active ingredient. The medicine is prepared by condensing and fermenting an extract from the ripened stems of Stevia Rebaudiana Bertoni by multi-stage condensation followed by fermentation and ripening of the condensed extract. It is effective for various skin diseases and other diseases caused by blood circulation insufficiency.

Abstract: Therapeutic as well as preventative measures to improve the cosmetic conditions or to alleviate the symptoms of dermatologic disorders with phenyl alpha acyloxyalkanoic acids and derivatives is disclosed. The cosmetic conditions and dermatologic disorders in humans in which the compounds may be useful include brittle or soft nails; abnormally thin skin, mucous membranes or wound; friction blisters; brittle hairs; pruritus; acne; and diseased nails, skin or mucous membranes due to natural or unnatural causes including but not limited to in flammations or infections. The phenyl alpha acyloxyalkanoic acids and derivatives include, for example, diphenyl alpha acetoxyacetic acid, phenyl alpha acetoxyacetic acid, phenyl alpha methyl alpha acetoxyacetic acid and phenyl alpha acetoxypropanoic acid. The compositions containing the active ingredients are also useful for treatment of skin, nails and hair conditions or disorders in domestic animals.

Abstract: Solubilized melanin based compositions supply melanin to skin, scalp and/or hair. The compositions consist of melanin, as an active ingredient, and a substance to solubilize the melanin blended together in a vehicle suitable for topical application. A melanin-based composition applied to the skin provides photoprotection of the human epidermis from exposure to ultraviolet rays. A melanin-based composition applied to wounds in the skin accelerates healing of the wounds. A melanin-based composition applied to the hair and scalp strengthens the hair.

Abstract: This invention provides compositions comprising a physiologically-active agent and a compound having the structural formula ##STR1## wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen, in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.

Abstract: The cutaneous atrophy associated with the use of steroids topically can be ameliorated using salts of certain .alpha.-hydroxyacids.

Abstract: A method is provided for treating a hypersensitivity disease comprising administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteractBACKGROUND OF THE INVENTIONThis invention was made with the assistance of NIH under grant number AI-09728. The U.S. Government has certain rights in the invention.

Abstract: A lenitive composition is provided for application to the skin of an anthralin patient for reducing anthralin-induced inflammation and the staining associated with anthralin use. The lenitive composition is a single phase aqueous treating solution comprising an organic amine and a film-forming agent dissolved within a nontoxic dermatologically acceptable carrier. The organic amine is selected from the group consisting of lower alkyl and lower alkanol primary, secondary and tertiary amines and comprises about 1 to 25 percent by weight of the single phase aqueous treating solution. The solution is topically applied to the anthralin-treated areas so as to completely cover the treated areas. The solution is applied before or after anthralin wash off, preferably in the form of a fine spray or mist.

Abstract: The use of sucralfate humid gel is described as vehicle for the application f drugs having topic activity (dermic and mucosal) and as basis for the formulation of beauty masks and other cosmetic preparations. Therapeutic and cosmetic formulations are described in the form of creams, ointments, aqueous dispersions comprising sucralfate humid gel.

Abstract: A method of treatment of inflammatory diseases which comprises administering, to a subject in need of such treatment, an anti-inflammatory effective amount of a polyoxyethylenesorbitan mono-higher-fatty acid ester.

Abstract: A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a natural, synthetic, or analog defensin molecule having both a mitogenic activity capable of stimulating cell growth and an antimicrobial activity capable of inhibiting the growth of a wide variety of pathogens. In addition to therapeutic use, the defensins are useful as mitogens in cell and tissue culture media.

Abstract: The subject invention relates to methods for regulating wrinkles in mammalian skin comprising topical application of a lysophosphatidic acid compound having the structure: ##STR1## or a cyclic derivative thereof having the structure: ##STR2## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH.sub.2 --.

Abstract: A method of treating human skin by topically administering an alkylmethylpolysiloxane having the formula ##STR1## in which x has a value of 1-300 and z has a value of 5-50.

Abstract: Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixture of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.

Abstract: This invention encompasses compounds and pharmaceutical compositions comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different members of the group consisting of 1,1-dimethylethyl, halo, phenyl and substituted phenyl wherein the substituents are selected from the group consisting of halo, hydroxy, lower alkyl and lower alkoxy, Alk is straight or branched chain lower alkylene; and R.sub.3 is lower alkoxycarbonylloweralkyl.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

Abstract: A composition comprising approximately equal proportions by volume of wintergreen oil, olive oil and/or oil of Eucalyptus and alcohol has an analgesic effect in treating aches and pains when rubbed or massaged on skin covering tissue from which such aches or pains emanate.

Abstract: Liquefiable powder compositions are disclosed for the delivery of topical analgesics. In particular, microporous cellulosic powders, such as cellulose acetates or nitrates, are disclosed as high liquid content vehicles for the delivery of liquid analgesic preparations. The resulting powders permit the application of the analgesic preparation by simply rubbing or otherwise applying the formulation onto the skin in such a manner that the powder liquefies and appears to vanish. Upon application, the frangible liquid loaded cellulosic powders break up into minute particles that do not pass easily beyond the initial layers of the skin, but do permit the slow release of the analgesic agent for absorption into the skin.

Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.

Abstract: A coated solid medicament form suitable for oral administration having reliable releasability of the active ingredient only in the large intestine is proposed. The medicament form is prepared by coating a core solid medicament form containing the active ingredient first with a chitosan having a specific degree of deacetylation and a specific degree of polymerization and then top-coated with a specific enteric-soluble polymer which is a hydroxypropyl methyl cellulose acetate succinate or a hydroxypropyl methyl cellulose hexahydrophthalate. The releasability of the active ingredient only in the large intestine can be more reliable when the core medicament form is, prior to coating with chitosan, provided with an enteric undercoating layer.

Abstract: The invention concerns a compound of the formula I, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl or naphthyl;A.sup.1 is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene;Ar.sup.2 is optionally substituted phenylene, or a 6 membered heterocyclene moiety containing up to three nitrogen atoms;R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; wherein R.sup.2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or substituted (1-4C)alkyl; and whereinR.sup.3 is hydroxy-(1-4C)alkyl, mercapto-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, (3-4C)alkenyloxy-(1-4C)alkyl, (3-4C)alkynyloxy-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkylthio-(1-4C)alkyl, (1-4C)alkylsulphinyl-(1-4C)alkyl, (1-4C)alkylsulphonyl-(1-4C)alkyl, (1-4C)alkoxycarbonyl-(1-4C)alkyl, (2-4C)alkanoyl-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl or cyano-(1-4C)alkyl; or R.sup.

Abstract: An anti-inflammatory cosmetic composition having a large effect of absorbing and shielding all of UV-A, UV-B and UV-C, small degeneration with the passage of time even upon absorption of light, small influence upon the skin, not lowered effect of absorbing light and high stability for heat is provided. This anti-inflammatory cosmetic composition comprises 0.1 to 20% by weight of a hydroxyaryl-s-triazine compound represented by the following structural formula in a cosmetically acceptable oil carrier: ##STR1## wherein R.sub.1 and R.sub.2 represent, same or different, hydrogen atoms, chlorine atoms, hydroxyl groups, alkoxy groups of 1 to 18 carbon atoms, aryloxy groups of 6 to 8 carbon atoms or mono- or dialkylamino groups containing 1 to 4 carbon atoms and R.sub.3 and R.sub.4 represent, same or different, hydrogen atoms, chlorine atoms, alkyl groups of 1 to 8 carbon atoms, methoxy groups or ethoxy groups.

Abstract: This invention encompasses a pharmaceutical composition comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of 1,1-dimethylethyl, halo, phenyl and substituted phenyl; Alk is straight or branched chain lower alkylene; R.sub.4 is hydrogen or lower alkyl; R.sub.3 is hydrogen or lower alkyl. The formulation of this invention are useful as anti-inflammatory and anti-allergy agents.

Abstract: A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain .omega.-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy- or epoxy-derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a)(b) esters are also claimed.

Abstract: Treatment of an animal with calcium flux inhibitors results in a decrease in the number of epidermal Langerhans cells and a simultaneous decrease in the ability to respond to contact sensitizing agents. Also, topical application of calcium flux inhibitors will reduce inflammation in patients experiencing delayed-type hypersensitivity reaction or atopic eczema. Thus, calcium flux inhibitors represent a new class of therapeutic agents in the treatment of contact dermatitis and eczema.

Abstract: A sebaceous excitosecretory agent comprising at least one of undecylenic acid, its salts, its esters, and its amide derivatives as an active ingredient. A process for exciting secretion of sebum comprising the step of applying onto a skin surface the above sebaceous excitosecretory agent. The sebaceous excitosecretory agent has a long-lasting action to excite secretion of sebum.

Abstract: A treating agent such as a wound therapeutic agent, inflammation therapeutic agent, hair growth agent and hair tonic, and a cosmetic, comprising as an effective component ovomacroglobulin are disclosed. They can act on the skin, a scalp or hairs to exhibit excellent wound curing promotion effect, hair growth promotion effect, and skin or hair protective effect.

Abstract: This invention pertains to a topically applied composition with a virucidal impact on mucocutaneous tissue. Ingredients essential to the efficacy of the formulated combination include a polyethylene glycol polymer known as Nonoxynol-9("N-9")in admixture with selected fat soluble vitamins A, D and E in the form of vegetable oil (and) retynyl palmitate (and) ergocalciferol together with tocopherol acetate. The invention is directed particularly to inactivation of herpes virus and human papilloma virus as manifested in cold sores, lesions, fever blisters, canker sores and warts. The N-9 contains viral activity while the vitamins effect restoration and strengthening of the damaged tissue cells.

Abstract: The invention relates to cosmetic and pharmaceutical compositions containing the derivatives of benzylidenecamphor of formula: ##STR1## where R.sub.1 denotes H, OH, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.8 alkoxy, R.sub.3 denotes OH, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.8 alkoxy, or else when R.sub.1 denotes H or OH, R.sub.3 can represent C.sub.1 -C.sub.8 alkyl, R.sub.2 and R.sub.4 denote H or OH, at least one of the radicals R.sub.2 and R.sub.4 representing OH.The compounds (I) are wide-band sunscreens and antioxidants, and are utilized in the treatment of cutaneous inflammations and allergies.

Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.

Abstract: Pharmaceutical and cosmetic compositions comprising extracts of Ammi visnaga and Ammi majus or the vasoactive agents contained therein are described.

Abstract: A pharmaceutical composition of a free amine benzophenanthridine alkaloid and a pharmaceutically acceptable carrier is disclosed. The composition is an antibacterial and antifungal agent.

Abstract: A family of compounds effective in inhibiting interleukin-1 (IL-1) production, interleukin-6 (IL-6), tumor necrosis factor (TNF) production, and the production of other leukocyte derived cytokines is comprised of oligomers and polymers of .alpha.1-4 linked L-guluronic acid residues which may be administered to a human or mammal in an amount sufficient to inhibit the production effect of leukocyte-derived cytokines. The inhibition of IL-1, IL-6 and TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

Abstract: A benzonaphthalene compound has the formula ##STR1## wherein R.sub.1 represents ##STR2## or (ii) --CH.sub.2 OH; R.sub.6 represents ##STR3## or OR.sub.7 wherein R.sub.7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R.sub.2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radical; R.sub.3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH.sub.3).sub.2 --R.sub.8 wherein R.sub.8 represents lower alkyl; and R.sub.4 and R.sub.5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjunctive tissues.